Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab + trastuzumab in HER2+ metastatic breast cancer patients previously treated with trastuzumab.
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
No association of HLA–DRB1 and TNF alleles in Mexican patients with autoimmune hepatitis